Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Nuvalent, Inc.Nuvalent Reports Increased Net Losses of $84.6 Million in Q1 2025
MARKETWISE, INC.MarketWise Reports 23.4% Revenue Decline and 30.7% Drop in Subscriber Count for Q1 2025
Lucky Strike Entertainment CorpLucky Strike Entertainment Reports 1% Revenue Growth to $339.9 Million in Q3 2025
Cronos Group Inc.Cronos Group Inc. Reports 28% Revenue Growth to $32.3 Million in Q1 2025
Rapport Therapeutics, Inc.Rapport Therapeutics Reports $24.1 Million Net Loss in Q1 2025, Increases R&D Spending
Aptose Biosciences Inc.Aptose Biosciences Reports $5.5 Million Net Loss and Pauses Luxeptinib Development
Vital Farms, Inc.Vital Farms Reports $162.2 Million Revenue, 10% Increase Year-Over-Year
Warner Music Group Corp.Warner Music Group Reports Revenue and Profit Decline in Q2 Fiscal 2025
Cullinan Therapeutics, Inc.Cullinan Therapeutics Reports $48.5 Million Net Loss in Q1 2025, Increases R&D Spending
Dyne Therapeutics, Inc.Dyne Therapeutics Reports $115.4 Million Net Loss in Q1 2025, Increases R&D Spending
Core Natural Resources, Inc.Core Natural Resources Reports $1.017 Billion Revenue and $69.3 Million Net Loss Following Arch Resources Merger
Commerce.com, Inc.BigCommerce Reports $82.4 Million Revenue in Q1 2025, Narrowing Net Loss
Q32 Bio Inc.Q32 Bio Reports $11 Million Net Loss in Q1 2025 Amid Restructuring and Clinical Focus
Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics Reports $84.9M Collaboration Revenue and $46.9M Net Income in Latest Quarter
HilleVax, Inc.HilleVax Reports Reduced Losses and Strategic License Agreement for Norovirus Vaccine
Werewolf Therapeutics, Inc.Werewolf Therapeutics Reports $18.1 Million Net Loss and No Revenue in Q1 2025
Cartesian Therapeutics, Inc.Cartesian Therapeutics Reports Revenue Decline and Net Loss in Q1 2025
Entrada Therapeutics, Inc.Entrada Therapeutics Reports Significant Decline in Q1 2025 Financial Performance
Vanda Pharmaceuticals Inc.Vanda Pharmaceuticals Reports $50M Revenue in Q1 2025, Net Loss Increases to $29.5M
ESSA Pharma Inc.ESSA Pharma Reports $6.4 Million Loss, Reviews Strategic Options After Clinical Trial Termination
Life Time Group Holdings, Inc.Life Time Group Holdings Reports 18.6% Revenue Growth to $706M in Latest Quarter
Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals Reports No Product Revenue and Significant Loss Reduction in Latest 10-Q
SHOPIFY INC.Shopify Reports 27% Revenue Growth to $2.36 Billion in Q1 2025
Verano Holdings Corp.Verano Holdings Reports Revenue Decline and Increased Net Loss in Q1 2025
INSMED IncInsmed Reports $256.6 Million Net Loss in Q1 2025, Despite 22.9% Revenue Growth